Results 61 to 70 of about 250 (109)
Pharmacologic treatment of fibromyalgia: an update. [PDF]
Front PharmacolLi Y +9 more
europepmc +1 more source
Response to Letter to the Editor Regarding "Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients With Narcolepsy: A Commentary". [PDF]
Neurol TherRuoff C, Candler S, Black J.
europepmc +1 more source
Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations. [PDF]
J Am Heart AssocKwon Y +6 more
europepmc +1 more source
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient's Perspective. [PDF]
CNS DrugsOrtiz LE +7 more
europepmc +1 more source
Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults [PDF]
Clinical Therapeutics, 2021 FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6, 7.5, and 9 g, require twice-nightly divided dosing, with the first dose taken at bedtime and the second 2.
David Seiden
exaly +10 more sources
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial [PDF]
Sleep, 2023 Yves Dauvilliers +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical TherapeuticsIndividuals with narcolepsy are more likely to be obese than the general population. Changes in weight-related measures with extended-release, once-nightly sodium oxybate (ON-SXB) and characteristics of participants with ≥5% weight loss were assessed in a Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium ...
Thomas Roth +2 more
exaly +3 more sources